GlassScriptPhysician profile
Tracey A Alves
NPI 1780038869
$3,431.56
in general payments reported to CMS, 2019-2025
29 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $409 · 2023: $417 · 2024: $837 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.03 | 2021-2025 | |
| Madrigal Pharmaceuticals | $582.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.85 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $239.12 | 2022-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $181.95 | 2022-2025 | Tremfya, Stelara |
| Celltrion USA INC. | $164.71 | 2025 | Vegzelma |
| Lilly USA, LLC | $127.31 | 2023-2025 | Omvoh, Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $108.49 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $104.86 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $97.55 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $94.05 | 2021-2023 | |
| Novo Nordisk INC | $90.85 | 2025 | Wegovy |
| Pfizer INC. | $85.93 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $68.02 | 2021-2022 | |
| Qol Medical, LLC | $62.14 | 2021-2025 | Sucraid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $58.99 | 2021-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $51.09 | 2023-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $50.43 | 2021-2024 | |
| Daiichi Sankyo INC. | $41.33 | 2022-2025 | Injectafer |
| Braintree Laboratories, INC. | $38.44 | 2021-2025 | Suflave |
| Ferring Pharmaceuticals INC. | $37.04 | 2022-2025 | Clenpiq |
| Exact Sciences Corporation | $25.02 | 2025 | The Cologuard Plus Collection Kit |
| Blueprint Medicines Corporation | $19.44 | 2024 | Ayvakit |
| Ironwood Pharmaceuticals, INC | $18.80 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.96 | 2025 | Iqirvo |
| Organon LLC | $16.00 | 2023 | Renflexis |
| Viiv Healthcare Company | $15.97 | 2023 | Dovato |
| Xeris Pharmaceuticals, INC. | $14.16 | 2024 | Gvoke Hypopen |
| Cumberland Pharmaceuticals, INC. | $12.76 | 2023 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Alves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.